Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy

Liver International

Volumn 28, Issue 6, 2008, Pages 787-797

  Färkkilä, Martti ^a   Rautiainen, Henna ^a   Kärkkäinen, Päivi ^a   Karvonen, Anna L ^b   Nurmi, Heimo ^c   Niemelä, Onni ^d  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d SEINÄJOKI CENTRAL HOSPITAL   (Finland)

Author keywords

Disease progression; Fibrosis markers; Histology; PBC; UDCA

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BIOLOGICAL MARKER; BUDESONIDE; CHOLESTANOL; HYALURONIC ACID; IMMUNOGLOBULIN; LIPID; PHYTOSTEROL; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; URSODEOXYCHOLIC ACID;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; FIBROGENESIS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; PRIMARY BILIARY CIRRHOSIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; THROMBOCYTE COUNT;

ANTI-INFLAMMATORY AGENTS; ASPARTATE AMINOTRANSFERASES; BILE ACIDS AND SALTS; BIOLOGICAL MARKERS; BIOPSY; BUDESONIDE; CHOLAGOGUES AND CHOLERETICS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FIBROSIS; HUMANS; HYALURONIC ACID; LIVER; LIVER CIRRHOSIS, BILIARY; LIVER FUNCTION TESTS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; PROSPECTIVE STUDIES; ROC CURVE; URSODEOXYCHOLIC ACID;

EID: 44949111378     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01722.x     Document Type: Article

References (31)

1. Kaplan MM. Primary biliary cirrhosis (review). N Engl J Med 1996; 335: 1570-8.
2. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OFW. Asymptomatic primary biliary cirrhosis: Clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004; 53: 865-70.
3. Nyberg A, Loof L. Primary biliary cirrhosis: Clinical features and outcome, with special reference to asymptomatic disease. Scand J Gastroenterol 1989; 24: 57-64.
4. Mahl TC, Schokcor W, Boyer JL. Primary biliary cirrhosis: Survival of a large cohort of symptomatic and asymptomatic patients. Followed for 24 years. J Hepatol 1994; 20: 707-13.
5. Beswick DR, Klatskin G, Boyer JL. Asymptomatic primary biliary cirrhosis. A progress report on long term follow-up and natural history. Gastroenterology 1985; 89: 267-71.
6. Poupon RE, Poupon R, Balkau B UDC-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330: 1342-7.
7. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90.
8. Combes B, Carithers RL, Maddrey WC, et al. A randomized double blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22: 759-66.
9. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999; 29: 644-7.
10. Corpechot C, Carrat F, Bonnand A-M, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 122, 32: 1196-9.
11. Pares A, Caballeria L, Rodes J, et al. Long term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial. UDCA Cooperative Group from Spanish association for the study of liver. J Hepatol 2000; 32: 561-6.
12. Corpechot C, Carrat F, Poupon RE, Poupon R. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol treated patients. Gastroenterology 2002; 122: 652-8.
13. Poupon RE, Lindor KD, Pares A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 12-6.
14. Mukherjee S, Sorrell MF. Noninvasive tests for liver fibrosis. Sem Liver Dis 2006; 26: 337-4.
15. Rockey DC, Bissell DM. Noninvasive tests of liver fibrosis. Hepatology 2006; 43: S113-20.
16. Leroy V, Hillert M-N, Sturm N, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 775-82.
17. Nyblom H, Björnsson E, Simren M, Aldenborg F, Almer S, Olsson R. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int 2006; 26: 840-5.
18. Corpechot C, Poujol-Robert A, Wendum D, et al. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int 2004; 24: 187-93.
19. Miettinen TA, Färkkilä M, Vuoristo M, et al. Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine. Hepatology 1995; 21: 1261-8.
20. Sudhop T, Sahin Y, Lindenthal B, et al. Comparison of the hepatic clearances of campesterol, sitosterol and cholesterol in healthy subjects suggests that efflux transporters controlling intestinal sterol absorption also regulate biliary secretion. Gut 2002; 51: 860-3.
21. Lee MH, Lu K, Hazard S, et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 2001; 27: 79.
22. Nikkilä K, Miettinen TA, Höckerstedt KVA, Isoniemi H. Sterol parameters as markers of liver function in primary biliary cirrhosis before and after liver transplantation. Transpl Int 2005; 18: 221-5.
23. Rautiainen H, Kärkkäinen P, Karvonen A-L, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial. Hepatology 2005; 41: 747-52.
24. Miettinen TA, Koivisto P. Noncholesterol sterols and bile acid production in hypercholesterolaemic patients with ileal by-pass. In: Baumgartner G, Stiehl A, Gerok W, eds. Bile Acid and Cholesterol in Health and Disease. Lancaster, UK: MTP Press, 1983; 183-7.
25. Miettinen TA. Gas-liquid chromatography determination of faecal neutral sterols using capillary column. Clin Chim Acta 1982; 124: 245-51.
26. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by simple predictive model. Hepatology 2002; 36: 986-92.
27. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
28. Ludvig J, Dicson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of biliary cirrhosis). Virchows Arch A 1978; 379: 103-12.
29. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
30. Pinzani M. Non-invasive evaluation of fibrosis: Don't count your chickens before they're hatched. Gut 2006; 55: 310-2.
31. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004; 127: 1704-13.